Lumosa Therapeutics Co., Ltd.'s board approved the exclusive licensing agreement of LT1001, a long-acting analgesic injection, with India?s Gufic Biosciences Ltd. (Gufic). Lumosa is responsible for supplying LT1001 to Gufic while Gufic is responsible for the clinical trials, registration, marketing, and sales of LT1001 in India.